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This dissertation is based on clinical investigations of the diagnosis, management, and
immunological aspects of cytomegalovirus (CMV) infections in renal and liver transplant
patients.
CMV is a member of the herpes virus family, that also comprises varicella-zoster virus,
herpes simplex virus, and Ebstein-Barr virus. About 50% of all adults have experienced
infection u'ith CMV, generally during infancy; the majority of these infections being
asymptomatic. CMV is not eliminated completely from the body after infection, but
remains present in a latent form. This latency can be recognized by the presence of
antibodies against CMV. Although the molecular basis of CMV latency is far from
understood, it is evident that antiviral immune responses are necessary to maintain this
state. In case of impaired function of the immune system (e.g., due to immunosuppressive
drugs, or to infection with the human immunodeficiency virus) CMV may reactivate and
cause disease.
CMV infection occurs in 50-70% of all transplant recipients, and may be the result of
reactivation of the endogeneous viral strain, or of transmission of the virus via the graft.
Fortunately, many infections remain asymptomatic because the immune system is still
sufficiently intact to mount rapid antiviral responses and limit the degree of viral
replication. CMV disease occurs predominantly when there has been no previous
exposure to CMV (and therefore no immunological memory exists that can be rapidly
recruited), or when the capacity to respond has been severely reduced by intensive
antirejection treatment. Clinical manifestations of CMV disease consist of high, often
spiking fevers, malaise and arthralgias, and may be accompanied by symptoms and signs
of organ involvement, especially esophagitis, gastritis, hepatitis or pneumonitis.
There are indications that CMV indirectly causes illness by exerting an
immunosuppressive effect that increases the susceptibility to other opportunistic agents.
The immune system plays a pivotal role with respect to the outcome of organ
transplantation. Therefore, chapter I first provides a short summary of the function of
this system, describing the way by which foreign antigens are recognized and eliminated.
This functioning is complicated in organ transplant recipients by the immunosuppressive
drugs prescribed in order to prevent rejection of the graft. These agents non-specifically
suppress immune reactivity, including responses against infectious organisms, resulting in
a greatly increased risk of opportunistic infections. CMV is the most frequent cause of
infections in transplant patients, and the remainder of chapter I describes the virological,
clinical and immunological aspects of CMV infection. Two recent developments in this
field form the basis of this thesis: the CMV antigenemia assay, a sensitive and
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quantitative method for early diagnosis and monitoring of infection; and the availability of
ganciclovir, a nucleoside analog that effectively suppresses viral replication and provides
the first specific therapeutic option against CMV.
Chapter 2 offers a working hypothesis for the relation between CMV and the host
immune system. This relation can be envisaged as a bilateral interaction: on the one hand,
the immune system suppresses viral replication. On the other, CMV negatively influences
host immunocompetence. During health a balance exists, with CMV subclinically just
active enough to stimulate low production of antibodies, yet otherwise kept in latency by
the immune system. This balance is disturbed by immunosuppressive treatment, with
CMV disease as a potential consequence. The viral replication during disease forms a
stimulus for the immune system to restore the initial balance. Treatment with antiviral
drugs only temporarily restores the balance, and the ultimate outcome depends on whether
antiviral immune responses have developed and are able to consolidate the treatment
result.
The main questions of this thesis follow directly from the working hypothesis: What rs the
value of CMV antigenemia es a diagnostic marker for CMV infection? What is the
importance of the viral load for the development of CMV disease? What are the effects of
antiviral therapy on clinical symptoms and on the viral load? What are the clinical and
immunological consequences of CMV infection for the immuune status of the patient?
Can early intervention with antiviral drugs limit the negative effect of CMV on the
immune system?
Chapter 3.l describes a comparison of the CMV antigenemia assay, viral isolation from
blood and urine, and serology for the early diagnosis of CMV infection in 72 renal
transplant patients. Antigenemia and serology oroved to be the most sensitive methods to
detect infection, but viral isolation performed equally well in diagnosing CMV disease.
Antigenemia could be detected 8 days before isolation of virus from blood, and 1l days
before onset of an antibody response against CMV.
Detection of viral DNA in clinical samples using the polymerase chain reaction (PCR)
represents a revolutionary development in the field of diagnostic virology. In an analysis
of 103 blood samples, PCR (89%) and the antigenemia assay (86%) proved to be more
sensitive than rapid viral isolation (45%).
These data indicate that the antigenemia assay and PCR are superior to raprd viral
isolation and serology with respect to early diagnosis of CMV infection after organ
transplantation.
Chapter 3.2 describes a study of the value of weekly testing of CMV antigenemia for the
early detection and monitoring of CMV disease in a gruup of 130 renal transplant
patients, 22 of which developed a CMV syndrome. In 19 (85%) of them, antigenemia
was present already before, or at the onset of, clinical symptoms. The pattern of
a'rtigenemia during infection correlated well with symptomatology. The maximum number
of antigen-positive cells during infection was higher, and the duration of antigenemia was
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infection. The baseline risk of a CMV syndrome was 19Vo, and rose to 42% upon
appearance of antigenemia. Combining antigen-positivity with well-known risk factors for
CMV disease led to the delineation of subgroups with significantly higher risk (60-86%)
of CMV syndrome. These categories are relevant for the development of earh
intervention strategies.
Differentiation of allograft rejection from CMV disease may be a difficult exercise. In
chapter 3.3 we analyzed in a group of 73 renal transplant patients 'ihether the
antigenemia assay is of additional value in this situation.
Absence of antigenemia practically excluded CMV as the cause o.- fever and allograft
dysfunction (of course, this does not prove that the abnormalities are due to rejection).
Eleven of the 39 rejection episodes occurred in the presence of CMV antigenemia. The
number of antigen-positive cells was helpful in diagnosing CMV disease in these cases: in
the l0 patients with asymptomatic infection (and concurrent rejection), this number was
< 10 positive cells per 50,000 PMN's whereas in the patients with CMV disease (and
rejection) this number ranged between 11 and 99.
If carefully interpreted, the antigenemia assay can be helpful in guiding the management
of these "difficult" cases.
Chapter 4. I describes the effects of antiviral treatment with ganciclovir on clinical
symptomatology and antigenemia levels in patients with severe CMV disease.
Eight of l1 patients rapidly improved under ganciclovir treatment; in 7/8, antigenemia
dropped concurrently with clinical improvement. Three patients had prolonged CMV
illness despite antiviral therapy. In these 3 antigenemia levels increased during the first
days of treatment.
Relapse of CMV disease after discontinuation of ganciclovir was associated with renewed
rises of antigenemia levels beyond l0 positive cells per 50,000 PMN's; antigenemia
remained below this level in patients with an uncomplicated recovery, or with other
complications (rejection, other infections). Viral isolation was generally negative during
antiviral treatment regardless of the clinical response.
Simultaneous steroid-resistant rejection and CMV infection forms a difficult therapeutic
dilemma. Treatment with anti-thymocyte globulin (ATG) or OKT3 may well lead to
severe CMV disease, but failure to administer intensiv: antirejection therapy will almost
certainly lead to graft loss. Chapter 4.2 presents a solution to this dilem;na. In 4 patierrt:
with this unhapppy combination, combined treetment for rejection and CMV infection was
instituted. This led to recovery of renal function, while mild or no symptoms of CMV
disease occuned. Two of the 4 patients had recurrent CMV dis:ase after ganciclovir was
stopped. Antigenemia testing proved useful, both for eaily recognition of infection as well
as fcr monitoring the effects of treatment.
Chaprer 4.3 summarizes the results of a pilot sLudy of the feasibility and efficacy of pre-
emptive treatment of primaiy CMV infection. CI\,IV syndromes occur in over 70% of aJl
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patients with primary infection: can disease be prevented by low-dose ganciclovir, started
when the patient still is asymptomatic?
Nine CMV seronegative patients were randomized upon appearance of antigenemia: 5
were treated expectantly, and 4 received ganciclovir at 50% of the usual therapeutic
dosage for l0 days. All 5 controls developed CMV disease within a few days after
randomization, but none of the patients on ganciclovir. However, after discontinuation of
ganciclovir 3 of the 4 preemptively treated patients had one or more episode(s) of CMV
disease, accompanied by exceptionally high viral loads. This may have been caused by
antirejection treatment, or may reflect a negative effect of antiviral therapy on the
development of antiviral immune responses.
There are indications that CMV infection negatively affects host immunocompetence. In
chapter 5.1 we investigated whether this is mediated by lymphocyte dusfunction.
Proliferation of lymphocytes in vitro in response to stimulation with immobilized aCD3
was signif,rcantly reduced in patients with CMV infection. Co-stimulation experiments
using oCD28 indicated that this pathway probably is intact.
The decreased proliferation rate was not just the result of a relative increase of activated,
poorly proliferating CD8+ T cells.
During CMV infection a median of 15% (range, 6-60) of all peripheral blood
lymphocytes were undergoing apoptosis (programmed cell death), whereas this number
was always lower than 5% in patients without CMV infection. The degree of apoptosis
was independent of the viral load. CMV-related apoptosis might be the result of defective
T-cell activation by CMV-infected antigen-presenting cells.
What are the clinical consequences of these in vitro cellular abnormalities? This question
forms the main topic of chapter 5.2, which contains an analysis of infectious
complications after orthotopic liver transplantation i a group of 111 consecutive patients.
The incidence of major infectious complications (other than CMV) during the first 30
days after transplantation was comparable in patients with and without (subsequent) CMV
infection. After that time, patients with CMV infection developed other major infections
significantly more often than those who did not have CMV infection. Interestingly, the
majority of these other major infections were caused by bacteria. This suggests that the
increased susceptibility to infections was caused by decreased barrier function of the skin
or mucosal surfaces, or impaired phagocytic function. Relatively few infections were
caused by fungi, yeasts, and protozoa (the principal opportunistic agents in patients with
abnormal T cell function), and their incidence was comparable in patients with and
without CMV infection. This finding may reflect the beneficial effect of timely reduction
of immunosuppression during CMV disease that prevented an increase in the number of
these life-threatening infections.
Chapter 6.1 describes the development of an ELISA system for the quantitative
measurement of IgM- and IgG antibodies against CMV. Using this method the levels of
antibodies during primary and secondary CMV infections after renal transplantation were
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Cellular immune responses probably form the cornerstone of the defense against CMV.
Monitoring these responses is technically difficult and too inconvenient for routine
implementation. We hypothesized that the activation status of peripheral blood
lymphocytes (that can be easily measured using flow cytometry) might form a (surrogate)
marker of cellular immune responses against CMV, and investigated this hypothesis in
renal transplant patients with primary and secondary CMV infection (chapter 6.2).
During the recovery phase of uncomplicated primary CMV infection the number of
activated CDSbrisht lymphocytes (cytotoxic T cells) and activated CD56* lymphocytes
(natural killer cells) strongly increased. During recovery from secondary infection, only
activated CD8bnsht cells increased. Numbers of these activated cells remained lowduring
severe, progressive primary CMV infection. These data suggest hat the activation status
of peripheral blood lymphocytes forms a surrogate marker of ceiiular immune responses
against CMV. Moreover, cellular and humoral immunity appear to have different roles in
the recovery from CMV infection: cellular responses interrupt viral replication, while
antibodies against CMV may give symptomatic improvement without changing the viral
load.
Cellular immune activation is associated with the release of several membrane molecules,
e.g.,IL-2R, CD4, CD8 and CD27. We evaluated in chapter 6.3 whether monitoring
these soluble products also forms a useful marker of cellular immune reactivity against
CMV.
Baseline levels of sCD4 were low, and remained within the range of normal during CMV
infection, whereas the other 3 markers significantly rose during CMV infection. Rises of
sCD8 showed the strongest increase, and occurred especially during recovery from
infection. However, in several patients CD8 (and the other markers) rose also during
progressive disease, indicating that activation of cytotoxic T cells is in itself not a
guarantee for effective antiviral effector responses.
Irvels of sCD8 and numbers of activated CD8brisht cells were strongly correlated.
However, in patients with progressive disease sCD8 often rose disproportionately high to
numbers of activated cells compared with patients with self-limited infection. This might
result from an increased rate of cell death of CD8bdeh'cells during progressive disease.
Chapter 5.6 contains an analysis of natural killer (NK) cell function in 15 renal transplant
patients with CMV infection. NK activity, as measured in a K562 lysis assay, increased
frcm 6Vo before infection to a peak value of 25 % during infection (P <.001), and
exceeded the upper level of controls in 9/15 cases. NK function was correlated with the
degree of activation of these ceils (as measured by flow cytometry) (r:.57, P <.001).
These data are consistent with a role for NK cells in recoverv from CMV infection.
As previously discussed, relapses of CMV disease after initially successful antiviral
treatment form a clinically relevant problem. We retrospectively analyzed in a group of
119
36 renal- and liver transplant patients whether these relapses can be predicted.
Clinical characteristics (CMV serostatus of donor and recipient, type of
immunosuppression, antirejection therapy, indication for antivirals) and virological
parameters (antigenemia levels before, during, or at the end of treatment, PCR positivity
after treatment) were not helpful in predicting subsequent relapse. However, antigenemia
levels rose strongly at the time of recurring disease: 10 or more antigen-positive cells per
50,000 PMN's occurred in 10/11 patients with, and 1/25 without relapse (P <.001).
Humoral immune responses at completion of treatment were of no predictive value in the
15 patients with primary infection, but absence of an IgG response in those with
secondary infection may be an indicator of impending relapse.
Numbers of activated CDSbrisht and CD56* lymphocytes at the end of antiviral treatment
were available from 15 patients. None of 8 patients with more than l00x1d/ml HLADR"
CD8b.cht cells had recurrent disease, whereas 6 of 7 patients with a lower number relapsed
(P <.01). No evident prognostic value of numbers of activated CD56* cells was found in
this small group of patients. These data suggest that specific cellular immune responses
determine the ultimate outcome of antiviral therapy.
Chapter 6 summarizes and integrates the results from the previous chapters. It is
concluded that viral load forms the most important determinant of CMV disease in this
category of immunosuppressed patients. The viral load is, in its turn, regulated by host
immune responses and antiviral therapy.
Not withstanding that many aspects of the immunopathogenesis of CMV disease, as well
as the specificity and regulation of immune responses are poorly understood, specific
guidelines for the management of transplant patients with CMV infection or CMV disease
are available.
This thesis concludes with some suggestions for further study.
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